These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 31013847)
21. Discriminating Immunorecognition Pathways Activated by RNA Nanostructures. Danai L; Johnson MB; Afonin KA Methods Mol Biol; 2023; 2709():229-240. PubMed ID: 37572284 [TBL] [Abstract][Full Text] [Related]
22. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786 [TBL] [Abstract][Full Text] [Related]
23. Modulating Immune Response with Nucleic Acid Nanoparticles. Durbin JK; Miller DK; Niekamp J; Khisamutdinov EF Molecules; 2019 Oct; 24(20):. PubMed ID: 31627288 [TBL] [Abstract][Full Text] [Related]
24. Immunostimulatory nucleic acid nanoparticles (NANPs) augment protective osteoblast and osteoclast type I interferon responses to Staphylococcus aureus. Mills EL; Avila YI; Beasock D; Radwan Y; Suptela SR; Marriott I; Afonin KA; Johnson MB Nanomedicine; 2024 Jun; 60():102762. PubMed ID: 38866196 [TBL] [Abstract][Full Text] [Related]
25. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Afonin KA; Dobrovolskaia MA; Ke W; Grodzinski P; Bathe M Adv Drug Deliv Rev; 2022 Feb; 181():114081. PubMed ID: 34915069 [TBL] [Abstract][Full Text] [Related]
26. Challenges to optimizing RNA nanostructures for large scale production and controlled therapeutic properties. Chandler M; Panigaj M; Rolband LA; Afonin KA Nanomedicine (Lond); 2020 May; 15(13):1331-40. PubMed ID: 32452262 [TBL] [Abstract][Full Text] [Related]
27. Small-Angle Scattering as a Structural Probe for Nucleic Acid Nanoparticles (NANPs) in a Dynamic Solution Environment. Oliver RC; Rolband LA; Hutchinson-Lundy AM; Afonin KA; Krueger JK Nanomaterials (Basel); 2019 May; 9(5):. PubMed ID: 31052508 [TBL] [Abstract][Full Text] [Related]
28. Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology. Afonin KA; Dobrovolskaia MA; Church G; Bathe M ACS Nano; 2020 Aug; 14(8):9221-9227. PubMed ID: 32706238 [TBL] [Abstract][Full Text] [Related]
29. Toehold-Mediated Shape Transition of Nucleic Acid Nanoparticles. Hartung J; McCann N; Doe E; Hayth H; Benkato K; Johnson MB; Viard M; Afonin KA; Khisamutdinov EF ACS Appl Mater Interfaces; 2023 May; 15(21):25300-25312. PubMed ID: 37204867 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of Nonmodified Wireframe DNA Origami for Acute Toxicity and Biodistribution in Mice. Wamhoff EC; Knappe GA; Burds AA; Du RR; Neun BW; Difilippantonio S; Sanders C; Edmondson EF; Matta JL; Dobrovolskaia MA; Bathe M ACS Appl Bio Mater; 2023 May; 6(5):1960-1969. PubMed ID: 37040258 [TBL] [Abstract][Full Text] [Related]
31. Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells. Saito RF; Rangel MC; Halman JR; Chandler M; de Sousa Andrade LN; Odete-Bustos S; Furuya TK; Carrasco AGM; Chaves-Filho AB; Yoshinaga MY; Miyamoto S; Afonin KA; Chammas R Nanomedicine; 2021 Aug; 36():102418. PubMed ID: 34171470 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of non-modified wireframe DNA origami for acute toxicity and biodistribution in mice. Wamhoff EC; Knappe GA; Burds AA; Du RR; Neun BW; Difilippantonio S; Sanders C; Edmondson EF; Matta JL; Dobrovolskaia MA; Bathe M bioRxiv; 2023 Mar; ():. PubMed ID: 36909507 [TBL] [Abstract][Full Text] [Related]
33. The Application of Light-Assisted Drying to the Thermal Stabilization of Nucleic Acid Nanoparticles. Anh Lam P; Furr DP; Tran A; McKeough RQ; Beasock D; Chandler M; Afonin KA; Trammell SR Biopreserv Biobank; 2022 Oct; 20(5):451-460. PubMed ID: 36067075 [No Abstract] [Full Text] [Related]